comprehensive -WSS

comprehensive

author：comprehensive 2025-10-03 01:06:17 - browse：47

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： 2015年7月11日知情人提供的在逃人员信息登记表显示，当天嫌疑人吴谢宇涉嫌在其母亲谢天琴住处杀死谢天琴后脱逃。

WSS

Histogen: Failed biotech offers rare public look inside

FDA authorizes Novavax’s updated Covid

3 questions for the future of Biden's cancer moonshot

Biogen shutters digital health group, ends Apple study, in cost cutting move

How one patient went off dialysis — and others can too

Chan Zuckerberg Biohub Chicago to focus on inflammation

knowledge

comprehensive

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

3 questions for the future of Biden's cancer moonshot

The cancer drug shortage isn’t new — and neither are the solutions

A virus, fished out of a lake, may have saved a man’s life

Alkermes shareholders re

What to expect at HLTH 2023, the health care industry conference

Novavax promises a turnaround & Lilly roils the obesity market

Menendez indictment could see pharma lose a key ally

United colonoscopy coverage change 'may cost lives,' doctors say

Chan Zuckerberg Biohub Chicago to focus on inflammation

focus

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Histogen: Failed biotech offers rare public look inside

AI can decode, harness the power of the humane immune system

FDA panel signals lack of confidence in Amgen cancer drug data

Histogen: Failed biotech offers rare public look inside

Address the ethical violations that led to 'Three Identical Strangers'

hotspot

entertainment

hotspot

leisure time